<abstract xmlns="http://www.w3.org/1999/xhtml"><p>Pancreatic cancer (PC) is an exceptionally lethal malignancy with increasing incidence and mortality worldwide. One of the principal challenges in the treatment of PC is that the diagnosis is usually made at a late stage when potentially curative surgical resection is no longer an option. General clinicians including internists and family physicians are well positioned to identify high-risk individuals and refer them to centers with expertise in PC screening and treatment where screening modalities can be employed. Here, we provide an up-to-date review of PC precursor lesions, epidemiology, and risk factors to empower the general clinician to recognize high-risk patients and employ risk reduction strategies. We also review current screening guidelines and modalities and preview progress that is being made to improve screening tests and biomarkers.</p><p>It is our hope that this review article will empower the general clinician to understand which patients need to be screened for PC, strategies that may be used to reduce PC risk, and which screening modalities are available in order to diminish the lethality of PC.</p></abstract>

Pancreatic cancer (PC) is an exceptionally lethal malignancy with increasing incidence and mortality worldwide. One of the principal challenges in the treatment of PC is that the diagnosis is usually made at a late stage when potentially curative surgical resection is no longer an option. General clinicians including internists and family physicians are well positioned to identify high-risk individuals and refer them to centers with expertise in PC screening and treatment where screening modalities can be employed. Here, we provide an up-to-date review of PC precursor lesions, epidemiology, and risk factors to empower the general clinician to recognize high-risk patients and employ risk reduction strategies. We also review current screening guidelines and modalities and preview progress that is being made to improve screening tests and biomarkers.It is our hope that this review article will empower the general clinician to understand which patients need to be screened for PC, strategies that may be used to reduce PC risk, and which screening modalities are available in order to diminish the lethality of PC.

Screening for pancreatic cancer: a review for general clinicians

Romanian Journal of Internal Medicine

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

{"article-title":"Screening for pancreatic cancer: a review for general clinicians"}

Pancreatic cancer (PC) is an exceptionally lethal malignancy with increasing incidence and mortality worldwide. One of the principal challenges in the...

Screening for pancreatic cancer: a review for general clinicians

Publicado en línea: 10 ago 2020

Páginas: 119 - 128

Recibido: 05 feb 2020

DOI: https://doi.org/10.2478/rjim-2020-0009

Palabras clave
pancreatic cancer, cancer screening, risk factors, risk reduction, biomarkers

© 2020 Nathaniel E. Wiest et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Screening for pancreatic cancer: a review for general clinicians

Publicado en línea: 10 ago 2020

Páginas: 119 - 128

Recibido: 05 feb 2020

DOI: https://doi.org/10.2478/rjim-2020-0009

Palabras clavepancreatic cancer, cancer screening, risk factors, risk reduction, biomarkers

© 2020 Nathaniel E. Wiest et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Palabras clave
pancreatic cancer, cancer screening, risk factors, risk reduction, biomarkers